HudBay Minerals Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (39)

View All

Latest Posts

About This Stock More About This Stock
Swing Trading Stock Watchlist For The New Year
Article By: Cory Mitchell, CMT
Sunday, January 3, 2021 4:37 PM EDT
The stock market is in good shape according to market health indicators. I am taking valid long trades as I see them. Here are the stock swing trading watchlists for Contraction Continuation Patterns for the US and Canadian markets as of Jan. 2.
In this article: DY, HBM, NIO, TGH, OESX, NUAN, IWM, SPX, FLGT
Read
Week In Review: Week's China Life Science Investments Total $800 Million
Article By: ChinaBio® Today
Saturday, December 19, 2020 12:23 PM EDT
Harbour BioMed completed a $221 million Hong Kong IPO to continue its novel drug development. Singlera Genomics, a San Diego-Shanghai genomics testing company, closed a $150 million Series B financing from China investors.
In this article: HBM, PFE, SCLN, ABBV, ALLO, ADCT, BNTX, LEGN
Read
Week In Review: Innovent Out-Licenses Ex-China Rights For PD-1 To Lilly In $1 Billion Deal
Article By: ChinaBio® Today
Saturday, August 22, 2020 1:53 PM EDT
Suzhou Innovent Bio expanded its 2015 alliance with Eli Lilly for Tyvyt®, Innovent's anti-PD-1 immunotherapy. In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets.
In this article: HBM, LLY, JUNO, JD, EYPT
Read
Week In Review: Shanghai Hansoh Enters $68 Million Deal For Leukemia Candidate
Article By: ChinaBio® Today
Saturday, August 1, 2020 1:34 PM EDT
Shanghai Hansoh Pharma obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment, plus milestones of up to $68 million. It will also pay royalties on sales.
In this article: HBM, PFE, SDGR, HMI
Read
Week In Review: Ocumension Climbs To $2.5 Billion Market Cap After $184 Million Hong Kong IPO
Article By: ChinaBio® Today
Saturday, July 11, 2020 12:05 PM EDT
Ocumension, a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion. The company has raised $200 million in venture capital.
In this article: ZLAB, TPTX, HBM
Read
All Posts

Latest Tweets for $HBM

No tweets yet!

PARTNER HEADLINES